Immune checkpoint inhibitors a new player in the therapeutic game of mesothelioma: New reality with new challenges.
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Clinical Trials, Phase I as Topic
Clinical Trials, Phase II as Topic
Clinical Trials, Phase III as Topic
Humans
Immune Checkpoint Inhibitors
/ administration & dosage
Mesothelioma
/ drug therapy
Pleural Neoplasms
/ drug therapy
Randomized Controlled Trials as Topic
Salvage Therapy
Immune checkpoint inhibitors
Ipilimumab
Mesothelioma
Nivolumab
Pembrolizumab
Journal
Cancer treatment reviews
ISSN: 1532-1967
Titre abrégé: Cancer Treat Rev
Pays: Netherlands
ID NLM: 7502030
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
received:
18
04
2021
revised:
06
06
2021
accepted:
12
06
2021
pubmed:
27
6
2021
medline:
28
8
2021
entrez:
26
6
2021
Statut:
ppublish
Résumé
Malignant pleural mesothelioma (MPM) is a rare and orphan thoracic malignancy, with a poor prognosis as the majority of patients are diagnosed with unresectable MPM, with no significant improvements in the therapeutic strategy for over a decade. However, the recent approval of immune checkpoint inhibitors (ICI) in treatment-naïve patients with unresectable MPM marks a significant step forward and hope for the treatment of this disease. In this narrative review, we discuss the biological rationale to use ICI in the treatment of MPM. We summarize the current evidence for the efficacy of ICI in MPM and discuss several unresolved challenges regarding the use of ICI in this disease, such as the best upfront immune approach in MPM (ICI versus ICI plus chemotherapy), the optimal sequential treatment strategy according to the first-line treatment, and the potential role of predictive biomarkers.
Identifiants
pubmed: 34174669
pii: S0305-7372(21)00098-0
doi: 10.1016/j.ctrv.2021.102250
pii:
doi:
Substances chimiques
Immune Checkpoint Inhibitors
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
102250Informations de copyright
Copyright © 2021 Elsevier Ltd. All rights reserved.